neutral
6 days agoCorona Remedies seeks growth capital through ongoing pharma IPO
Corona Remedies’ ₹655 crore pharmaceutical IPO is open for subscription from December 8 to 10 in a price band of ₹1,008–1,062 per share. The generic drug maker reported Q2 sales of ₹450 crore, growing 18% year-on-year. Proceeds will be used for manufacturing capacity expansion amid steady sector growth. The company is expected to list on December 15 on the main exchanges.
Companies:
- Corona Remedies
Tags:
- ipo
- pharma
neutral
6 days agoCorona Remedies seeks growth capital through ongoing pharma IPO
Corona Remedies’ ₹655 crore pharmaceutical IPO is open for subscription from December 8 to 10 in a price band of ₹1,008–1,062 per share. The generic drug maker reported Q2 sales of ₹450 crore, growing 18% year-on-year. Proceeds will be used for manufacturing capacity expansion amid steady sector growth. The company is expected to list on December 15 on the main exchanges.
Companies:
- Corona Remedies
Tags:
- ipo
- pharma
Explore:Mutual Fund Themes
1 min read
62 words
Corona Remedies’ ₹655 crore pharma IPO remains open as the company targets capacity expansion following strong Q2 sales growth.
Corona Remedies’ ₹655 crore pharmaceutical IPO is open for subscription from December 8 to 10 in a price band of ₹1,008–1,062 per share. The generic drug maker reported Q2 sales of ₹450 crore, growing 18% year-on-year. Proceeds will be used for manufacturing capacity expansion amid steady sector growth. The company is expected to list on December 15 on the main exchanges.
Corona Remedies’ ₹655 crore pharmaceutical IPO is open for subscription from December 8 to 10 in a price band of ₹1,008–1,062 per share. The generic drug maker reported Q2 sales of ₹450 crore, growing 18% year-on-year. Proceeds will be used for manufacturing capacity expansion amid steady sector growth. The company is expected to list on December 15 on the main exchanges.
Companies:
- Corona Remedies
Tags:
- ipo
- pharma
- ipo
- pharma
- corona remedies
Dec 9, 2025 • 17:50